Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Free Cash Flow (2019 - 2025)

Pulmonx (LUNG) has disclosed Free Cash Flow for 7 consecutive years, with -$8.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 24.14% to -$8.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$33.2 million, a 0.86% increase, with the full-year FY2024 number at -$32.9 million, up 12.63% from a year prior.
  • Free Cash Flow was -$8.1 million for Q3 2025 at Pulmonx, down from -$4.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$4.0 million in Q2 2025 to a low of -$15.5 million in Q1 2022.
  • A 5-year average of -$9.7 million and a median of -$9.1 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 73.22% in 2021, then skyrocketed 39.97% in 2025.
  • Pulmonx's Free Cash Flow stood at -$10.2 million in 2021, then rose by 11.15% to -$9.1 million in 2022, then rose by 7.01% to -$8.5 million in 2023, then grew by 6.5% to -$7.9 million in 2024, then dropped by 2.48% to -$8.1 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Free Cash Flow are -$8.1 million (Q3 2025), -$4.0 million (Q2 2025), and -$13.2 million (Q1 2025).